The problem with highs and lows...
Insulin dosing for meals is one of the greatest challenges to blood glucose control. Inaccurate dosing can lead to high and low blood glucose levels that are associated with negative health complications, can be disconcerting and extremely unpleasant to experience, lead to hospitalization, and can be very costly.
In 2011, there were 282,000 admissions to the Emergency Room in the United States for extreme low blood glucose levels known as hypoglycemia (1). It is estimated that 30 percent of all visits to the ER for hypoglycemia result in hospitalization (2).
Overall, the estimated total cost of visits to the ER and hospitalization due to hypoglycemia in 2011 was $1.8 billion (2-5).
DugalDiabetes is a diabetes app that improves the accuracy of insulin dosing for meals by using the diabetic's own data, machine learning, and real-time feedback to reduce the frequency of high and low blood glucose levels after eating.
Instead of chasing highs and lows all day, DugalDiabetes makes it easier to focus on all the other things that matter in life.
At DugalHealth, we strive to improve public health through applied technologies. Specific to our current goal, we believe technology should be leveraged to facilitate the decision making process that is integral to type 1 diabetes management.
Our DugalHealth team has extensive years of experience with type 1 diabetes (T1D) management, nutrition, business, and data analytics. Founded by Michael Fox, a Registered Dietitian and type 1 diabetic for 28 years, DugalHealth is integrating their expertise with the DugalDiabetes application. DugalHealth has created partnerships with leading diabetes research institutions, key diabetes medical professionals, and people living with type 1 diabetes. In November 2016, DugalDiabetes was awarded 1st place in the Mobileys mobile application competition.
"Conceptually, DugalDiabetes represents a truly unique and significantly more comprehensive approach to insulin dosing optimization. It has the potential to greatly reduce blood sugar variability which translates to fewer complications of diabetes and vastly improved quality of life for many patients with diabetes. It also represents a wonderful complement to new insulin pump technology, which has “learning” software to improve overnight blood sugar but is still far from being able to do the same for blood sugar fluctuation related to meals.
I hope to offer my patients DugalDiabetes through clinical trials as soon as available, because I believe strongly that it has the potential to dramatically advance diabetes care, not only in type 1 diabetes but for all patients using insulin."
- Michael Vlases MD, FACP, CMIO
Drop us a line...
Learn More - Partner with us - Be part of our initial rollout
Awards and Affiliations